TONGHUA DONGBAO PHARM. sees an upgrade to Slightly Positive due to a better fundamental star rating
The general evaluation of TONGHUA DONGBAO PHARM. (CN), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date February 23, 2021, the closing price was CNY 12.54 and its potential was estimated at CNY 14.58.Tonghua Dongbao Pharmaceutical is engaged in the production and distribution of prepared Chinese and Western medicine, biological products and related medicine preparations. Co.'s products consist of gene-recombinant insulin lyophilized powders, botanical drugs, capsules, tablets, mixtures, small capacity injection, large capacity injection, powder and injection preparation, ointment, nasal drop, syrup, tincture, raw medicine, operating room, emergency room and consulting room equipment and instruments. In addition, Co. is also engaged in the manufacture and sales of health care products, package materials, wild vegetables, edible fungus, and plastic building materials.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.